NCT01095302View on ClinicalTrials.gov

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Neoplasms, Malignant
Interventions
DRUG

OMBRABULIN (AVE8062)

"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"

DRUG

cisplatin

"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"

DRUG

docetaxel

"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"

Trial Locations (3)

Unknown

Investigational Site Number 392003, Akashi-Shi

Investigational Site Number 392001, Kōtoku

Investigational Site Number 392002, Nagoya

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY